otenabant

Otenabant (CP-945,598) is a potent and selective small molecule antagonist of the cannabinoid type 1 (CB1) receptor. Developed by Pfizer, it was investigated primarily for the treatment of obesity and weight management. Otenabant exhibits high affinity for CB1 receptors (Ki = 0.7 nM in binding assays) and shows over 10,000-fold selectivity against the CB2 receptor[2][4][8]. The drug acts by blocking CB1-mediated signaling pathways involved in appetite regulation and energy balance. In phase 3 clinical trials, otenabant demonstrated dose-dependent weight loss and improved glycemic control in overweight or obese patients with or without type 2 diabetes[3][6]. However, its development was discontinued due to changing regulatory perspectives on the risk/benefit profile of CB1 antagonists as a class rather than specific safety concerns with otenabant itself[5].

Other names

otenabant